FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016356714> ?p ?o ?g. }

• W2016356714 endingPage "1757" @default.
• W2016356714 startingPage "1749" @default.
• W2016356714 abstract "The use of lytic viruses to preferentially infect and eliminate cancer cells while sparing normal cells is a promising experimental therapeutic approach for treating cancer. However, the efficacy of oncolytic virotherapy is often limited by two innate immunity pathways, the protein kinase PKR and the 2′-5′-oligoadenylate (OAS)/RNase L systems, which are widely present in many but not all tumor cell types. Previously, we reported that the anticancer drug, sunitinib, an inhibitor of VEGF-R and PDGF-R, has off-target effects against both PKR and RNase L. Here we show that combining sunitinib treatments with infection by an oncolytic virus, vesicular stomatitis virus (VSV), led to the elimination of prostate, breast, and kidney malignant tumors in mice. In contrast, either virus or sunitinib alone slowed tumor progression but did not eliminate tumors. In prostate tumors excised from treated mice, sunitinib decreased levels of the phosphorylated form of translation initiation factor, eIF2-α, a substrate of PKR, by 10-fold while increasing median viral titers by 23-fold. The sunitinib/VSV regimen caused complete and sustained tumor regression in both immunodeficient and immunocompetent animals. Results indicate that transient inhibition of innate immunity with sunitinib enhances oncolytic virotherapy allowing the recovery of tumor-bearing animals. The use of lytic viruses to preferentially infect and eliminate cancer cells while sparing normal cells is a promising experimental therapeutic approach for treating cancer. However, the efficacy of oncolytic virotherapy is often limited by two innate immunity pathways, the protein kinase PKR and the 2′-5′-oligoadenylate (OAS)/RNase L systems, which are widely present in many but not all tumor cell types. Previously, we reported that the anticancer drug, sunitinib, an inhibitor of VEGF-R and PDGF-R, has off-target effects against both PKR and RNase L. Here we show that combining sunitinib treatments with infection by an oncolytic virus, vesicular stomatitis virus (VSV), led to the elimination of prostate, breast, and kidney malignant tumors in mice. In contrast, either virus or sunitinib alone slowed tumor progression but did not eliminate tumors. In prostate tumors excised from treated mice, sunitinib decreased levels of the phosphorylated form of translation initiation factor, eIF2-α, a substrate of PKR, by 10-fold while increasing median viral titers by 23-fold. The sunitinib/VSV regimen caused complete and sustained tumor regression in both immunodeficient and immunocompetent animals. Results indicate that transient inhibition of innate immunity with sunitinib enhances oncolytic virotherapy allowing the recovery of tumor-bearing animals." @default.
• W2016356714 created "2016-06-24" @default.
• W2016356714 creator A5021085703 @default.
• W2016356714 creator A5022073372 @default.
• W2016356714 creator A5057121925 @default.
• W2016356714 creator A5059509650 @default.
• W2016356714 creator A5067358586 @default.
• W2016356714 date "2013-09-01" @default.
• W2016356714 modified "2023-09-25" @default.
• W2016356714 title "Suppression of Antiviral Innate Immunity by Sunitinib Enhances Oncolytic Virotherapy" @default.
• W2016356714 cites W1481896249 @default.
• W2016356714 cites W1511743510 @default.
• W2016356714 cites W1588006079 @default.
• W2016356714 cites W1665842545 @default.
• W2016356714 cites W1967587727 @default.
• W2016356714 cites W1969390441 @default.
• W2016356714 cites W1969962178 @default.
• W2016356714 cites W1970677867 @default.
• W2016356714 cites W1974515735 @default.
• W2016356714 cites W1989535705 @default.
• W2016356714 cites W1997634655 @default.
• W2016356714 cites W2000884139 @default.
• W2016356714 cites W2002589386 @default.
• W2016356714 cites W2003781492 @default.
• W2016356714 cites W2023310830 @default.
• W2016356714 cites W2031475459 @default.
• W2016356714 cites W2031913105 @default.
• W2016356714 cites W2032884648 @default.
• W2016356714 cites W2039391338 @default.
• W2016356714 cites W2042433752 @default.
• W2016356714 cites W2046013214 @default.
• W2016356714 cites W2050921603 @default.
• W2016356714 cites W2053032921 @default.
• W2016356714 cites W2061742276 @default.
• W2016356714 cites W2065319149 @default.
• W2016356714 cites W2066324183 @default.
• W2016356714 cites W2069249210 @default.
• W2016356714 cites W2089157311 @default.
• W2016356714 cites W2090732350 @default.
• W2016356714 cites W2095537460 @default.
• W2016356714 cites W2096602182 @default.
• W2016356714 cites W2109746877 @default.
• W2016356714 cites W2110410873 @default.
• W2016356714 cites W2114067488 @default.
• W2016356714 cites W2120736516 @default.
• W2016356714 cites W2125733229 @default.
• W2016356714 cites W2128892990 @default.
• W2016356714 cites W2142247394 @default.
• W2016356714 cites W2150701651 @default.
• W2016356714 cites W2156408558 @default.
• W2016356714 cites W2158474413 @default.
• W2016356714 cites W2163285372 @default.
• W2016356714 cites W2171167766 @default.
• W2016356714 cites W2171499496 @default.
• W2016356714 cites W4211238487 @default.
• W2016356714 doi "https://doi.org/10.1038/mt.2013.112" @default.
• W2016356714 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3776628" @default.
• W2016356714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23732991" @default.
• W2016356714 hasPublicationYear "2013" @default.
• W2016356714 type Work @default.
• W2016356714 sameAs 2016356714 @default.
• W2016356714 citedByCount "55" @default.
• W2016356714 countsByYear W20163567142013 @default.
• W2016356714 countsByYear W20163567142014 @default.
• W2016356714 countsByYear W20163567142015 @default.
• W2016356714 countsByYear W20163567142016 @default.
• W2016356714 countsByYear W20163567142017 @default.
• W2016356714 countsByYear W20163567142018 @default.
• W2016356714 countsByYear W20163567142019 @default.
• W2016356714 countsByYear W20163567142020 @default.
• W2016356714 countsByYear W20163567142021 @default.
• W2016356714 countsByYear W20163567142022 @default.
• W2016356714 countsByYear W20163567142023 @default.
• W2016356714 crossrefType "journal-article" @default.
• W2016356714 hasAuthorship W2016356714A5021085703 @default.
• W2016356714 hasAuthorship W2016356714A5022073372 @default.
• W2016356714 hasAuthorship W2016356714A5057121925 @default.
• W2016356714 hasAuthorship W2016356714A5059509650 @default.
• W2016356714 hasAuthorship W2016356714A5067358586 @default.
• W2016356714 hasBestOaLocation W20163567141 @default.
• W2016356714 hasConcept C121608353 @default.
• W2016356714 hasConcept C136449434 @default.
• W2016356714 hasConcept C159047783 @default.
• W2016356714 hasConcept C161238802 @default.
• W2016356714 hasConcept C182615771 @default.
• W2016356714 hasConcept C203014093 @default.
• W2016356714 hasConcept C2522874641 @default.
• W2016356714 hasConcept C2776178377 @default.
• W2016356714 hasConcept C2779057330 @default.
• W2016356714 hasConcept C2779490328 @default.
• W2016356714 hasConcept C29537977 @default.
• W2016356714 hasConcept C49744831 @default.
• W2016356714 hasConcept C502942594 @default.
• W2016356714 hasConcept C54355233 @default.
• W2016356714 hasConcept C82210918 @default.
• W2016356714 hasConcept C82495950 @default.
• W2016356714 hasConcept C86803240 @default.
• W2016356714 hasConcept C8891405 @default.

• next